source
- Alnylam to launch larger study of RNA therapy for Huntington’s diseaseAlnylam Therapeutics announced it will expand its clinical program for an RNA‑based drug aimed at treating Huntington’s disease. The decision comes amid a challenging landscape for neurodegenerati…
- Alnylam's experimental Huntington's therapy reduces mutant protein in early trialAlnylam Pharmaceuticals reported early data from a small study of its gene‑silencing drug for Huntington's disease. The investigational agent, brezosiran, was administered at several dose levels.…